SPAC Research & Analysis
SPAC research, analysis, and data trusted by leading SPAC sponsors, investors, banks, and more.
SPAC Research & Analysis
Boardroom Alpha writes daily SPAC analysis covering the SPAC market, SPAC deals and mergers, IPOs, sponsors and more.
Blade Therapeutics Vote Delayed
The race against the clock continues. BIOT says it has enough votes for its merger with Blade Therapeutics, but needs more time to close. And the rest of the day’s news in SPACs.
Will Grove Collaborative Make it Over the Goal Line?
The Branson-backed sustainable consumer goods company reports soft Q1 results ahead of 6.14 merger vote. June’s going to be a nail biter– a slew of extension and merger votes coming up.
Seatgeek and Forbes Cancelled
An oversaturated SPAC market yields a combination of terminations and extensions as deal pressure intensifies. And the rest of the day’s news in SPACs.
SPAC Market Review – May 2022
Inflation, rising interest rates, and reduced corporate earnings across the board have led to persistent market gyrations which prove its too early for bottom fishing. The stampede out of deSPACs now makes it ‘deal-or-die’ time for those without targets.
Two SPAC deals as the clock keeps ticking
Two SPAC deals today; some important votes this week. And the rest of the day’s news in SPACs.
Despite an Icy SPAC Market, S-1s Keep Coming
The week ends with a third automotive tech deal announcement. S-1s continue to be filed. And the rest of the day’s news in SPACs.
Automotive Tech in Focus
Two DAs today in auto tech, one would represent China’s biggest U.S. listing since Didi. WeWork fires its CFO. And the rest of the day’s news in SPACs.
Social Platform Uplive Said to Be Exploring SPAC
Social platform Uplive said to be exploring SPAC. DA for LGTO and construction services provider Southland Holdings. And the rest of the day’s news in SPACs.
Wag! on Why Pet Care is a Growing Post-Pandemic Play
Garrett Smallwood, CEO of Wag! explains why the pet care segment is immune to inflationary fears and poised for post-pandemic growth.
MSP Recovery Sinks
MSP Recovery (MSPR) sinks, falling 53% on its debut. Biote gets approval. Lots of extension votes ahead. And the rest of the day’s news in SPACs.
MSP Recovery Debuts Tomorrow
Medicare and Medicaid secondary payer reimbursement recovery specialist MSP Recovery (MSPR) begins trading tomorrow. Extension for TINV/Grindr. And the rest of the day’s news in SPACs.
Comera Life Sciences Debuts in the Red
Comera Life Sciences (CMRA), the maker of self-injectible biologics, deSPAC’d today, closing down 9%. An updated look at deSPAC count and redemption rates. And the rest of the day’s news in SPACs.